Age-related Macular Degeneration (AMD) Drugs Market
完整報告名稱與涵蓋範圍
Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Distribution by Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User and Segment Forecasts, 2024-2031
報告摘要
With a 2023 valuation of USD 9.58 Bn, the global Age-related Macular Degeneration (AMD) Drugs Market is anticipated to increase to USD 19.77 Bn by 2031, demonstrating a CAGR of 9.7% during the 2024–2031 forecast window.
The Age-related Macular Degeneration (AMD) Drugs sector involves a degenerative eye disease commonly occurring after the age of 50, leading to vision loss in the inner area of the visual field. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region anticipated to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Age-related Macular Degeneration (AMD) Drugs Market Snapshot
Chapter 4. Global Age-related Macular Degeneration (AMD) Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Age-related Macular Degeneration (AMD) Drugs Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Age-related Macular Degeneration (AMD) Drugs Industry Trends
Chapter 5. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. Market Share by Products, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Products:
5.2.1. Lucentis
5.2.2. Eylea & Eylea HD
5.2.3. Vabysmo
5.2.4. Syfovre
5.2.5. Other Products
Chapter 6. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 2: By Molecules, Estimates & Trend Analysis
6.1. Market Share by Molecules, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Molecules:
6.2.1. Ranibizumab
6.2.2. Aflibercept
6.2.3. Faricimab
6.2.4. Pegcetoplan
6.2.5. Other Molecules
Chapter 7. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 3: By Type of AMD, Estimates & Trend Analysis
7.1. Market Share by Type of AMD, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of AMD:
7.2.1. Wet AMD
7.2.2. Dry AMD
Chapter 8. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 4: By Approval type, Estimates & Trend Analysis
8.1. Market Share by Approval type, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Approval type:
8.2.1. Biologic
8.2.2. Biosimilar
Chapter 9. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 5: By End Users, Estimates & Trend Analysis
9.1. Market Share by End Users, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:
9.2.1. Hospitals
9.2.2. Specialty Centers
9.2.3. Long-Term Care Facilities
Chapter 10. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Age-related Macular Degeneration (AMD) Drugs Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031
10.2.3. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031
10.2.4. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031
10.2.5. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031
10.2.6. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031
10.3. Europe
10.3.1. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031
10.3.3. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031
10.3.4. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031
10.3.5. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031
10.3.6. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031
10.4.3. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031
10.4.4. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031
10.4.5. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By Approval type, 2024-2031
10.4.6. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By End Users, 2024-2031
10.5. Latin America
10.5.1. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031
10.5.3. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031
10.5.4. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031
10.5.5. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031
10.5.6. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031
10.6.3. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031
10.6.4. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031
10.6.5. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031
10.6.6. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Regeneron Pharmaceuticals Inc. (US)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Bayer AG (Germany)
11.2.3. F. Hoffmann-La Roche AG (Switzerland)
11.2.4. Novartis AG (Switzerland)
11.2.5. Apellis Pharmaceuticals, Inc. (US)
11.2.6. Coherus BioSciences, Inc. (US)
11.2.7. Astellas Pharma Inc. (Japan)
11.2.8. Biogen (US)
11.2.9. STADA Arzneimittel AG (Germany)
11.2.10. Formycon AG (Germany)
11.2.11. Biocon. (India)
11.2.12. Outlook Therapeutics, Inc. (US)
11.2.13. Intas Pharmaceuticals Ltd. (India)
11.2.14. Teva Pharmaceutical Industries Ltd. (Israel)
11.2.15. Chengdu Kanghong Biotech Company (China)
11.2.16. Sandoz Group AG (Switzerland)
11.2.17. Stealth BioTherapeutics Inc. (US)
11.2.18. Ocular Therapeutix, Inc. (US)
11.2.19. Opthea Limited, Inc. (Australia)
11.2.20. Kodiak Sciences Inc. (US)
11.2.21. Innovent Biologics, Inc. (China)
11.2.22. Bio-Thera Solution Inc. (China)
11.2.23. Alvotech (Iceland)
11.2.24. Alteogen Inc. (South Korea)
11.2.25. Shanghai Henlius Biotech, Inc. (China)
11.2.26. Amgen Inc. (US)
11.2.27. Ocumension Therapeutics. (China)
11.2.28. Adverum Biotechnologies, Inc. (US)
11.2.29. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們